What determines the presence of systemic acidosis is summarized in Box 2. To produce urine that is normally acid relative to blood, the kidney must excrete net acid (ingested and metabolically generated H + of around 40± 70 mmol/day, depending on diet)Ða process facilitated by the main urinary buffers of phosphate and ammonium (NH 4 + )Ðand must reclaim ®ltered bicarbonate. The main sites of H + secretion that sustain these two components of 221
The past decade has seen much progress in our understanding of the cellular mechanisms responsible for renal tubular acidosis (RTA), although the mechanism of the common complication of nephrocalcinosis remains unclear. In this brief overview, we discuss RTA from the standpoint of applied or`clinical' renal tubular physiology, since this represents a synthesis of over 50 years of clinical description and classi®cation, more than 30 years of segmental renal tubular physiology, and almost 10 years of applied molecular genetics. We begin by de®ning RTA and its current clinical classi®cation, and we review this in the context of normal urinary acidi®cation and how it might go wrong. DEFINITION RTA signi®es an inability of the kidney to excrete adequately an acid (H + ) load and so contribute to maintaining normal acid±base balance. De®ned in this way, it could also include the low acid excretion of renal failure, but RTA is distinguished from uraemic acidosis by a normal or only slightly reduced glomerular ®ltration rate (GFR) and a hyperchloraemic normal (rather than increased) anion gap metabolic acidosisÐthe only other important cause of which is loss of alkali (bicarbonate) from diarrhoea. In uraemic acidosis H + excretion per functioning nephron is increased; the underlying cellular mechanisms of H + secretion are preserved and responding normally to a systemic acid-load that cannot be excreted because of too few nephrons 1 .
The current classi®cation of RTA can be confusing, especially the older terminology of`types', which was originally chronological (Box 1). This terminology gives no hint as to the process of renal acid excretion and therefore to the potentially defective underlying cellular mechanism 2 . Advances in renal physiology, and most recently in molecular genetics as applied to renal tubular cell physiology, have now made it possible to describe RTA in more functional terms and even to predict likely causes.
To illustrate this, we must ®rst describe how the kidney maintains long-term acid±base balance.
RENAL ACID EXCRETION
The following equation, a loose version of the Henderson± Haselbalch relationship, highlights the kidney's critical role in bicarbonate balance as well as its place in normal acid± base balance 3 :
. Type 1: Distal RTA (most common)Ð`complete' and incomplete' (hypokalaemia common)
. acid±base balance are the proximal and distal tubules, where the reclamation of ®ltered bicarbonate and the excretion of net acid occur, respectively; these nephron sites are also the basis of proximal versus distal RTA ( Figure 1 ). Figure 2 shows the major pathways of acidi®cation along the renal tubule. At each site the secreted H + is generated inside the renal tubular cell from CO 2 and H 2 O, catalysed by the enzyme carbonic anhydrase (CA±II). This enzyme is especially important along the proximal tubule, where its presence on the luminal cell membrane surface (as another isoform, CA±IV) promotes the combination of ®ltered bicarbonate with secreted H + by dehydrating the carbonic acid (H 2 CO 3 ) produced, leading to net bicarbonate reabsorption (via CO 2 diffusion).
In addition to secreting H + , the proximal tubular cells can generate new bicarbonate from the metabolism of glutamine, which also produces ammonium (NH 4 ), the key urinary buffer (see Box 2) . Ammonium reaches the urine by a complex route that involves proximal tubular secretion, subsequent reabsorption along the thick ascending limb of the loop of Henle and lastly diffusion trapping within the collecting duct lumen and so to the ®nal urine. Its journey to urine can be disrupted at each step and thereby impair net acid excretion, even when cellular H + secretion is normal. As an example, hyperkalaemia (especially when due to a lack of aldosterone, see Box 1) can reduce acid excretion by inhibiting NH 4 + production 4 .
The actual mechanisms of cellular H + secretion described so far are illustrated in Figure 3 . In the proximal tubule most of the H + secretion is coupled to Na + absorption via the Na + -H + exchanger (which also transports NH 4 + to secrete it from the proximal tubular cells) of which several isoforms have been cloned 5, 6 . Isoform 3 (NHE-3) appears to be the main transporter responsible for luminal H + (and NH 4 + ) secretion 7 , but so far has not been linked to a form of clinical RTA. In addition to the Na + ±H + exchanger there is an Na + ±independent H + secretory mechanism, the electrogenic H + -ATPase 8 , although this proton pump' is functionally much more important in H + secretion along the distal tubule and collecting duct, where its activity also depends on aldosterone.
To achieve luminal H + secretion, bicarbonate must leave the cell across the opposite (basolateral) cell membrane. In the proximal tubule this is mainly via the Na + ±HCO 3 7 co-transporter, whereas in the distal nephron (distal tubule and collecting duct) it is via the Cl À ±HCO 3 7 exchanger. Each of the transporters shown in Figure 3 is a potential target in acquired or inherited forms of RTA. However, to date only the H + -ATPase 9±12 , Cl 7 ±HCO 3 7 exchanger 13±16 and Na + ±HCO 3 7 co-transporter 17 secondary to reduced bicarbonate transport) is only one potential mechanism of RTA; others are set out in Box 4.
DIAGNOSIS
An important clue in RTA is the relationship between plasma bicarbonate concentration and urine pH. In proximal RTA, bicarbonate is lost in the urine and urine pH may initially be high but will fall to 55.5 as the plasma bicarbonate concentration decreases; in contrast, in distal RTA, urine pH remains raised despite a low plasma bicarbonate (Figure 4 ). The diagnosis of RTA is usually suspected when the urine pH is inappropriately, or persistently, alkaline; but remember that urine pH also depends on time of day and diet. A more useful random or spot urine pH value is that of an early morning urine sample (second void), when acid excretion is usually maximal and pH normally 55.5. A`clinic' dipstick urine pH is a very rough guide and is often unreliable: urine pH must be measured with a pH electrode soon after voiding; if urine is left standing or there is infection, it can be misleadingly high, at 8 or more.
In proximal RTA, urine pH may be high or appropriately low, depending on the plasma bicarbonate concentration (see earlier). In the absence of other clues suggesting a Fanconi-like defect of proximal tubular function, such as glycosuria, aminoaciduria, phosphate wasting, or tubular (low-molecular-weight) proteinuria, it may be necessary to do intravenous bicarbonate loading and measure the fractional excretion of bicarbonate. Normally urinary bicarbonate is barely detectable and fractional excretion is 55% of the (glomerular) ®ltered load, but in proximal RTA it is usually around 15%. In distal RTA, urine pH will be high, but plasma bicarbonate concentration can be low (`complete distal RTA') or normal (`incomplete distal RTA') 20 . For a clear demonstration of impaired renal net acid excretion a urinary acidi®cation test must be done, either by acute administration of an acid load as oral ammonium chloride (NH 4 Cl, 0.1 g/kg) 21 or by the combination of oral¯udrocortisone (0.1 mg) and frusemide (40 mg) 22 . In both tests urine pH is measured as urine is voided for at least 5 hours; in the NH 4 Cl test, up to 8 hours may be necessary because of the time needed to ingest it without nausea or vomiting. A normal response is a fall in urine pH at some point to 55.5.
Underlying distal RTA is an important cause of nephrocalcinosis and renal stone disease. In the most comprehensive clinical series published, Wrong 23 reported that approximately 20% of over 300 patients with nephrocalcinosis had underlying distal RTA, inherited or acquired. Of the inherited type most were dominantly inherited, and of the acquired type most were autoimmune (e.g. Sjo Ègren's syndrome) 9, 24 . It is therefore important to consider the possibility of distal RTA in any patient with renal stones, particularly if nephrocalcinosis is also present. . Failure of H + generation (e.g. lack of carbonic anhydrase)
.`Leaky' apical (luminal) cell membrane (e.g. amphotericininduced)
. Failure of NH 4 + generation or`circulation' within the kidney (e.g. hyperkalaemia-induced)
Box 4 Mechanisms of renal tubular acidosis
and depends on identifying ectatic terminal collecting ducts on intravenous urography. However, the associated calci®cation and medullary damage (and loss of normal collecting duct function) can produce a secondary form of distal RTA. In isolated nephrocalcinosis in women, the cause is often autoimmune and the condition is commonly associated with symptomatic hypokalaemia 23 . The reason for nephrocalcinosis and renal stones in RTA is not completely understood, but hypercalciuria (usually con®ned to those patients with systemic acidosis) and low urinary excretion of citrate are important factors. Indeed a low urinary citrate concentration in the presence of an alkaline pH is an important clue to underlying distal RTA, since there is normally a direct relationship between urinary citrate concentration and urine pH. Citrate reaches the urine by ®ltration but is partly reabsorbed in the proximal tubule, where its absorption depends on pH, systemic and intracellular, such that acidosis increases citrate reabsorption and also its intracellular metabolism 25 . It is probably for this reason that kidney stones and nephrocalcinosis are less common in proximal RTA: citrate reabsorption is often reduced and urinary citrate excretion increased, although this may be offset by any associated hypokalaemia and intracellular acidosis. In distal RTA, systemic and/or intracellular acidosis leads to increased citrate reabsorption in the proximal tubule and thus reduced urinary citrate excretion; hence a potential bene®t of alkali therapy in correcting this.
As already mentioned, hypokalaemia is often associated with RTA. In proximal RTA, the most likely reason is the increase in bicarbonate delivery and¯ow rate to the main site of K + secretion, the distal nephron. However, there is no clear explanation for the hypokalaemia commonly observed in distal RTA. In both forms of RTA, treatment with oral bicarbonate or citrate (which is converted to bicarbonate in the liver) tends to exacerbate the hypokalaemia.
TREATMENT OF RTA
The main reasons for treatment are to protect the bones and help heal rickets or osteomalacia in those patients with metabolic acidosis, and to promote citrate excretion, which may reduce the risk of renal stones and progression of nephrocalcinosis 26 . Box 5 lists common management strategies. Ideally, in those patients with metabolic acidosis, plasma bicarbonate concentration should be maintained above 20 mmol/L. In proximal RTA, a thiazide diuretic can be helpful by causing mild volume depletion, which enhances proximal tubular reabsorption of bicarbonate; however, as with bicarbonate supplements, it will increase the tendency to hypokalaemia.
THE FUTURE
Monogeneic disorders of renal tubular function will continue to provide insights into the complexities and subtleties of urinary acidi®cation, even when RTA is not the main clinical feature. For example, the tubulopathy now known as Dent's disease, genetically characterized by Thakker 27 and co-workers, can sometimes be confused with distal RTA. Its mutated protein, an intracellular Cl À channel, ClC-5, may regulate H + secretion by a mechanism akin to that well-described for water channels (aquaporin 2) 28 , with insertion and retrieval of proton pumps into the luminal plasma membraneÐan interpretation that may also be consistent with a recent ®nding by Karet et al. 12 in a recessively inherited form of distal RTA.
The puzzle of exactly how and why nephrocalcinosis occurs in distal RTA remains unsolved. Now that speci®c H + transporter defects are known to be important in clinical RTA, it should be possible to reproduce such abnormalities in isolated renal collecting duct cells and study the process of microcrystallization leading to nephrocalcinosis and renal stone formation. . Alkali therapy in small doses: 1±2 mmol/kg, target plasma [HCO 3 7 ]420 mmol/L to heal bones to prevent stones/limit progression of nephrocalcinosis . K + supplements may be necessary Finally, knowledge of the gene targets holds out the prospect of gene therapy 29, 30 , not just for those with inherited defects of renal acidi®cation, but also as supplementary therapy in those with secondary forms of RTA and renal stone disease.
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